By Novo Nordisk…
Novo Nordisk Pharmatech celebrates a century of insulin
Koege, Denmark: – World-leading recombinant insulin and quaternary ammonium compounds (Quats) specialist Novo Nordisk Pharmatech A/S is celebrating the 100th Anniversary of insulin production by its parent company Novo Nordisk.
Novo Nordisk became a pioneering producer of insulin in 1923, only months after the first isolation of the peptide hormone from a canine pancreas and its successful injection into a human patient. This was a milestone in human medicine as a first way of treating diabetes that had previously been a fatal condition.
The breakthrough was also highly influential in establishing Novo Nordisk as a pharmaceutical leader driving medical changes. Since 1923, significant improvements in how insulin is manufactured and administered to patients have made diabetes treatment progressively safer and simpler.
Novo Nordisk Pharmatech has been able to take advantage of this unrivalled experience to manufacture recombinant insulin to the most rigorous standards as not only a vital therapy but also a universal cell culture ingredient for the manufacturing of a broad range of therapeutic agents, from monoclonal antibodies to cell and gene strains and vaccines.
The ever-greater importance of technical insulin as a manufacturing agent has been demonstrated during the Covid pandemic, with an upsurge in global demand for insulin in the race to discover new vaccines and therapies.
Novo Nordisk Pharmatech CEO Ulla Grove Krogsgaard Thomsen commented: “Supplying technical insulin to the world-leading manufacturers of therapeutic drugs, our company is proud to bring insulin into the development of other life-changing drugs, improving patients’ lives.”
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical raw materials for the pharmaceutical and biopharmaceutical industries. The company specializes in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients as well as delivering Recombinant Insulin for use in cell culture media to enhance cell growth and viability, and productivity.
Novo Nordisk Pharmatech A/S helps the world´s largest pharmaceutical and biopharmaceutical industries reduce their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals and acquired by Novo Nordisk in 1986. The company is operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.
You can learn more about Novo Nordisk Pharmatech at novonordiskpharmatech.com.